Name: Biologics manufacturing in uncertain times
Start: 2025-08-28T16:30:00-07:00
End: 2025-08-28T18:30:00-07:00
Location: The Hangar

Join us for an engaging EPPIC meetup focused on actionable strategies to navigate the evolving landscape of biologics manufacturing. From leveraging AI in bioprocessing to building resilient global supply chains, this event will highlight real-world case studies, expert perspectives, and technology spotlights designed to accelerate innovation while managing risk.

This event is jointly hosted by our sponsors for the event [Kemwell Biopharma](https://www.kemwellbiopharma.com/) & [Bioprocess.ai](https://bioprocess.ai/)

\*\*Time:\*\*4:30 PM – 7:00 PM

**Agenda Highlights:**
**Opening Keynote (45 min):**
**Kemwell Biopharma** – *A One-Stop Solution to Accelerate Your Biologics Pipeline*
Includes a case study of a U.S. biotech gaining timeline advantage through integrated, end-to-end manufacturing at a single site.

**Technology Spotlight (30 min):**
**Bioprocess AI** – *Leveraging AI in Bioprocessing to Drive Speed, Quality, and Scalability*

**Case Study Presentation (30 min):**
Preliminary Evaluation of Combining AI and CDMO Capabilities to Reduce Cycle Time and Enhance Data Management

**Panel Discussion (40 min):**
*Building a Resilient Biologics Supply Chain Beyond China – Evaluating Western CDMOs vs. Emerging Hubs like India and APAC*

**Moderator:** TBD

**Panelists:**

* Mr. Rangan (VP, Protein Science and Early CMC, CytomX)
* Mr. Mohan Srinivasan (Associate VP, Biologics Oncology)
* Ms. Amita Goel (Founder, Celtheon)

**Who Should Attend:**
Biotech and pharma professionals, CDMO leaders, CMC and supply chain experts, AI innovators, and investors interested in the future of biologics manufacturing.

**About our sponsors:**

**Kemwell Biopharma**
Located in Bangalore, India, Kemwell Biopharma is an end-to-end biologics CDMO with fully integrated development and cGMP manufacturing services from process design through commercial drug product. Their platform supports mammalian cell culture for mAbs, bispecifics and fusion proteins, with >4,500 L reactor capacity and automated fill/finish operations, all operating at the site of development. Trusted by global pharma since 1980 and accredited by stringent international audits, Kemwell enables scalable biologics delivery with agility and regulatory compliance.

**Bioprocess.AI**
Founded in 2023, Bioprocess.AI delivers a SaaS platform tailored for bioprocess scientists, acting as an AI “co‑pilot” through development, scale‑up, and manufacturing. With tools like SmartELN for automated documentation, run‑to‑run analytics, predictive monitoring, and one‑click CMC insights, Bioprocess.AI accelerates translation from bench to clinic while reducing manual bottlenecks.

Venkatesh

Hiranjith Hariharan

EPPIC Global

Health & Wellbeing

Expat Indian

Technology

Digital Health

Pharmaceutical Industry

Medical Devices

AI and Society

Innovation

Biotechnology

Biologics manufacturing in uncertain times

The Hangar

Share

EPPIC Global

Biologics manufacturing in uncertain times

EPPIC Global

Details

Members are also interested in